InvestSMART

INOVIQ Ltd (ASX:IIQ)

ALERT: Price-sensitive ASX Announcement for IIQ
Current share price for IIQ : $0.220 -0.3 (-57.69%)+
Announcement
Release
25 Jun 2026 8:46AM
Price at Release
$0.520
Full Release
download
Summary
INOVIQ Ltd has announced positive in vitro data regarding its CAR-exosome platform, which has shown strong tumour-killing activity in ovarian cancer cell lines. The study, focused on CA125- and EGFR-targeting CAR-exosomes, demonstrated rapid tumour cell killing with up to 90% efficacy in some ovarian cancer cells. The CAR-exosomes also showed effectiveness against the aggressive SK-OV-3 cell line. These findings highlight the platform's potential across multiple hard-to-treat cancers, including ovarian cancer, triple-negative breast cancer, and non-small cell lung cancer. INOVIQ is advancing towards clinical trials with an aim for first-in-human studies by 2028.
Key Points
  • INOVIQ demonstrated in vitro efficacy of CAR-exosomes in ovarian cancer cell lines.
  • CA125- and EGFR-targeting CAR-exosomes achieved up to 90% tumour cell killing.
  • CAR-exosomes also effective in aggressive SK-OV-3 cell line.
  • Platform shows potential in hard-to-treat cancers such as TNBC and NSCLC.
  • INOVIQ plans first-in-human studies by 2028.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.